Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study
- PMID: 7796410
Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study
Abstract
Recently, we demonstrated that an androgen-regulated cell adhesion molecule, C-CAM, acts as a tumor suppressor in prostate cancer development. In this study, we further explored the possibility of applying C-CAM as a potential agent for developing prostate cancer gene therapy using an adenoviral delivery system. We found that prostate cancer cells, in general, were sensitive to adenoviral infection. In vitro characterization indicated that C-CAM1 protein was detected only in C-CAM1 adenovirus-infected cells but not in antisense control virus-infected cells, and the levels of expression showed dose dependency. Because of the stability of the protein, C-CAM expression in viral-infected cells appeared to be a long-lasting event, indicating that C-CAM may be superior to many other known tumor suppressors that have a short protein half-life. Most importantly, the delivery of a single dose of C-CAM adenovirus was able to repress the growth of PC-3-induced tumors in nude mice for at least 3 weeks. Taken together, these data indicate that C-CAM is a potential candidate for human prostate cancer therapy.
Similar articles
-
Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.Semin Oncol. 1999 Apr;26(2):227-33. Semin Oncol. 1999. PMID: 10597733 Review.
-
Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model.Anticancer Res. 1999 Jan-Feb;19(1A):337-40. Anticancer Res. 1999. PMID: 10226564
-
Human prostate cancer progression models and therapeutic intervention.Hinyokika Kiyo. 1997 Nov;43(11):815-20. Hinyokika Kiyo. 1997. PMID: 9436028 Review.
-
Suppression of human bladder cancer growth by increased expression of C-CAM1 gene in an orthotopic model.Cancer Res. 1996 Aug 1;56(15):3431-5. Cancer Res. 1996. PMID: 8758907
-
Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches.Cancer Res. 1995 Jan 1;55(1):190-7. Cancer Res. 1995. PMID: 7805032
Cited by
-
The transmembrane domain of CEACAM1-4S is a determinant of anchorage independent growth and tumorigenicity.PLoS One. 2012;7(1):e29606. doi: 10.1371/journal.pone.0029606. Epub 2012 Jan 3. PLoS One. 2012. PMID: 22235309 Free PMC article.
-
Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil adhesion to endothelial cells.J Transl Med. 2008 Dec 10;6:78. doi: 10.1186/1479-5876-6-78. J Transl Med. 2008. PMID: 19077207 Free PMC article.
-
Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.Prostate. 2009 Feb 15;69(3):234-48. doi: 10.1002/pros.20867. Prostate. 2009. PMID: 19016247 Free PMC article.
-
Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms.Mol Cancer. 2008 May 28;7:46. doi: 10.1186/1476-4598-7-46. Mol Cancer. 2008. PMID: 18507857 Free PMC article.
-
CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation.J Clin Invest. 2004 Oct;114(7):944-52. doi: 10.1172/JCI21786. J Clin Invest. 2004. PMID: 15467833 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical